Kite Pharma Inc (KITE) Stake Lessened by Stifel Financial Corp

Stifel Financial Corp reduced its position in shares of Kite Pharma Inc (NASDAQ:KITE) by 86.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,380 shares of the biopharmaceutical company’s stock after selling 22,047 shares during the period. Stifel Financial Corp’s holdings in Kite Pharma were worth $609,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the company. Teacher Retirement System of Texas lifted its position in shares of Kite Pharma by 8.7% during the 3rd quarter. Teacher Retirement System of Texas now owns 3,967 shares of the biopharmaceutical company’s stock worth $713,000 after purchasing an additional 316 shares during the last quarter. Prudential Financial Inc. lifted its position in shares of Kite Pharma by 8.2% during the 3rd quarter. Prudential Financial Inc. now owns 5,410 shares of the biopharmaceutical company’s stock worth $973,000 after purchasing an additional 410 shares during the last quarter. Aperio Group LLC lifted its position in shares of Kite Pharma by 7.6% during the 3rd quarter. Aperio Group LLC now owns 6,755 shares of the biopharmaceutical company’s stock worth $1,215,000 after purchasing an additional 476 shares during the last quarter. Ameritas Investment Partners Inc. lifted its position in shares of Kite Pharma by 17.5% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,292 shares of the biopharmaceutical company’s stock worth $445,000 after purchasing an additional 638 shares during the last quarter. Finally, California State Teachers Retirement System lifted its position in Kite Pharma by 0.8% in the second quarter. California State Teachers Retirement System now owns 86,578 shares of the biopharmaceutical company’s stock valued at $8,976,000 after acquiring an additional 709 shares during the last quarter. 87.72% of the stock is owned by institutional investors and hedge funds.

Shares of Kite Pharma Inc (KITE) opened at $179.79 on Friday. Kite Pharma Inc has a 1 year low of $39.82 and a 1 year high of $179.95. The firm has a market cap of $10,280.00 and a price-to-earnings ratio of -26.06.

WARNING: “Kite Pharma Inc (KITE) Stake Lessened by Stifel Financial Corp” was first published by Community Financial News and is the property of of Community Financial News. If you are viewing this piece on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright legislation. The original version of this piece can be read at https://www.com-unik.info/2017/12/30/kite-pharma-inc-kite-stake-lessened-by-stifel-financial-corp.html.

Kite Pharma Profile

Kite Pharma, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Its therapy involves modifying a patient’s T cells outside the patient’s body, or ex vivo, causing the T cells to express chimeric antigen receptors (CARs), or T cell receptors (TCRs), and then reinfusing the engineered T cells back into the patient.

Institutional Ownership by Quarter for Kite Pharma (NASDAQ:KITE)

Receive News & Ratings for Kite Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kite Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit